-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Nilotinib (NIL) is a tyrosine kinase inhibitor (TKI) initially shown to be effective in chronic phase (CP) chronic myeloid leukemia (CML) resistant or intolerant patients twice daily 400mg, well tolerated
This report reports a 10 -year follow-up study that enrolled 73 adult patients (median age, 51 years, range 18-83) newly diagnosed with chronic phase (CP)-chronic myeloid leukemia (CML) to study Nigeria.
10
Figure 1: Duration of NIL 400 mg treatment during the first 5 years of the study
Figure 1: Duration of NIL 400 mg treatment during the first 5 years of the study
Figure 2: 10-Year Overall Survival
Figure 2: 10-Year Overall SurvivalThe 10-year major (MMR) and deep (MR4) molecular response rates were 96% and 83%, respectively
Figure 3: Remission without treatment
Figure 3: Remission without treatment
72.
Figure 4: Cumulative incidence of arterial occlusive events
Figure 4: Cumulative incidence of arterial occlusive events
Overall, the long-term results of this research study demonstrate that first-line use of NIL is able to induce stable TFR in a relevant number of patients
Original source:
Original credits: Gugliotta G, Castagnetti F, Breccia M, Levato L, Intermesoli T, D'Adda M, Salvucci M, Stagno F, Rege-Cambrin G, Tiribelli M, Martino B, Bocchia M, Cedrone M, Trabacchi E, Cavazzini F, Porretto F, Sorà F, Simula MP, Albano F, Soverini S, Foà R, Pane F, Cavo M, Saglio G, Baccarani M, Rosti G.Treatment-free remission in chronic myeloid leukemia patients treated front-line with nilotinib : 10-year follow-up of the GIMEMA CML 0307 study.
Haematologica; https://doi.
org/10.
3324/haematol.
2021.
280175 [Early view].
Gugliotta G, Castagnetti F, Breccia M, Levato L, Intermesoli T, D'Adda M, Salvucci M, Stagno F, Rege-Cambrin G, Tiribelli M, Martino B, Bocchia M, Cedrone M, Trabacchi E, Cavazzini F, Porretto F, Sorà F, Simula MP, Albano F, Soverini S, Foà R, Pane F, Cavo M, Saglio G, Baccarani M, Rosti G.
Treatment-free remission in chronic myeloid leukemia patients treated front-line with nilotinib: 10- year follow-up of the GIMEMA CML 0307 study.
Haematologica; https://doi.
org/10.
3324/haematol.
2021.
280175 [Early view].
Leave a comment here
